1H-1,2,3-苯并噻唑-4-胺 | 18076-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 1H-1,2,3-苯并噻唑-4-胺
• 中文别名: 1H-1,2,3-苯并三唑-4-胺盐酸盐；1H-苯并[D][1,2,3]三唑-4-胺盐酸盐
• 英文名称: 1H-1,2,3-benzotriazol-4-amine
• 英文别名: benzotriazole-4-amine；4-Aminobenzotriazole；1H-benzo[1,2,3]triazol-4-ylamine；1H-benzotriazol-4-ylamine；1H-Benzotriazol-4-ylamin；1H-benzotriazol-4-amine；2H-benzotriazol-4-amine
• CAS: 18076-61-4
• 化学式: C₆H₆N₄
• mdl: MFCD00962622
• 分子量: 134.14
• InChiKey: ZDWPBMJZDNXTPG-UHFFFAOYSA-N

物化性质

• 熔点：
  148-150°
• 沸点：
  479.4±18.0 °C(Predicted)
• 密度：
  1.480±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  1H-1,2,3-苯并噻唑-4-胺 生成 4-羟基苯并三唑
  参考文献：
  名称：

  Fries; Gueterbock; Kuehn, Justus Liebigs Annalen der Chemie, 1934, vol. 511, p. 213,240

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲基苯并三氮唑 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、413.69 kPa 条件下， 反应 3.0h， 生成 1H-1,2,3-苯并噻唑-4-胺
  参考文献：
  名称：

  Novel Dimroth rearrangements of the benzotriazole system: 4-amino-1-(arylsulfonyl)benzotriazoles to 4-[(arylsulfonyl)amino]benzotriazoles

  摘要：

  A variety of mono- and diarylsulfonyl-substituted 4-aminobenzotriazoles were prepared. Thermal rearrangements of 4-amino-1-(arylsulfonyl)benzotriazoles to 4-[(arylsulfonyl)amino]benzotriazoles were observed and confirmed by separation of the rearrangement products. Their structures were characterized by spectral methods and by X-ray crystallography. The rearrangement rates were studied by variable-temperature NMR experiments. Crossover experiments support an intramolecular mechanism involving a heterolytic benzotriazole ring cleavage to form a diazo intermediate followed by recyclization to the 4-amino group.

  DOI：

  10.1021/jo00027a036

文献信息

• Synthesis of N- aryl and N -heteroaryl hydroxylamines via partial reduction of nitroarenes with soluble nanoparticle catalysts
  作者：Jefferson H. Tyler、S. Hadi Nazari、Robert H. Patterson、Venkatareddy Udumula、Stacey J. Smith、David J. Michaelis

  DOI：10.1016/j.tetlet.2016.11.105

  日期：2017.1

  ruthenium nanoparticles enable the selective hydrazine-mediated reduction of nitroarenes to hydroxylamine products in high yield and selectivity. Key to obtaining the hydroxylamine product in good yield was the use of organic solvents capable of solubilizing the polystyrene-supported nanoparticle catalyst. N-aryl and N-heteroaryl hydroxylamines are generated under exceptionally mild conditions and in

  聚苯乙烯负载的钌纳米颗粒能够以高收率和选择性将肼介导的硝基芳烃选择性还原为羟胺产物。以高收率获得羟胺产物的关键是使用能够溶解聚苯乙烯负载的纳米颗粒催化剂的有机溶剂。N-芳基和N-杂芳基羟胺是在异常温和的条件下，在各种容易还原的官能团存在下生成的。
• [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098421A1

  公开（公告）日：2017-06-15

  The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代苯并噻二嗪衍生物。具体而言，本发明涉及式(I)化合物：其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病，如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Schering Corporation

  公开号：US20040106794A1

  公开（公告）日：2004-06-03

  There are disclosed compounds of the formula 1 or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。
• Pyrimidines and uses thereof
  申请人：Cell Therapeutics, Inc.

  公开号：US20040204386A1

  公开（公告）日：2004-10-14

  The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor-cells.

  这项发明涉及嘧啶类化合物及其用途，包括抑制溶磷脂酸酰基转移酶β（LPAAT-β）活性和/或抑制肿瘤细胞等细胞的增殖。
• [EN] HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS<br/>[FR] AGENTS ANTIFONGIQUES DÉRIVÉS DE PYRIDINE SUBSTITUÉS PAR UN HÉTÉROCYCLE
  申请人：AMPLYX PHARMACEUTICALS INC

  公开号：WO2019113542A1

  公开（公告）日：2019-06-13

  Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

  本文描述了杂环取代吡啶衍生物抗真菌药剂和包含该化合物的药物组合物。这些化合物和组合物对于治疗真菌病和感染是有用的。